標(biāo)題: Titlebook: Acute Promyelocytic Leukemia; A Clinical Guide Oussama Abla,Francesco Lo Coco,Miguel A. Sanz Book 2018 Springer International Publishing AG [打印本頁] 作者: 揭發(fā) 時間: 2025-3-21 18:47
書目名稱Acute Promyelocytic Leukemia影響因子(影響力)
作者: 發(fā)微光 時間: 2025-3-21 20:41 作者: 索賠 時間: 2025-3-22 03:01 作者: floodgate 時間: 2025-3-22 06:41 作者: 極力證明 時間: 2025-3-22 11:00
Minimal Residual Disease in APL,g.Von den Gro?en lernen: Firmenbeispiele zu MAB-Folgeprozess.Die Mitarbeiterbefragung als Instrument der Feedbackgewinnung und Organisationsentwicklung wird in gro?en und mittleren Unternehmen zunehmend h?ufiger eingesetzt. In vielen F?llen wird es aber vers?umt, die nach der eigentlichen Befragung 作者: 無彈性 時間: 2025-3-22 14:05 作者: ineptitude 時間: 2025-3-22 20:34 作者: 執(zhí) 時間: 2025-3-22 23:54
An Attempt to Connect to the Oceanfied, characterized, and cured. The determination of a precise molecular definition of the genetic defect and the emergence of an antidogmatic paradigm have made the history of APL a model for the treatment of malignancies. However, the new concepts of in vivo malignant cell differentiation and cell作者: 繼而發(fā)生 時間: 2025-3-23 01:45
Rik van der Linden,Maartje Schermervation of RA signaling upon activation of PML/RARA by its ligand. Over the years, evidence from mouse models has questioned the key role of transcriptional reactivation in clinical remissions. The striking activity of arsenic trioxide, a compound which does not affect normal RA, argued for the exist作者: PACK 時間: 2025-3-23 06:28
Rik van der Linden,Maartje Schermerd growth, as well as for response to treatments..The hierarchical model of tumor organization is an old concept that gained attention in the past 20 years, upon the development of xenotransplantation assays. This allowed the characterization of a rare cell population, namely, the leukemic stem cells作者: 抗原 時間: 2025-3-23 12:34
Mary Jean Walker,Wendy A. Rogersytic leukemia gene (PML) with the C-terminus of retinoic acid receptor alpha (RARα) to produce the PML-RARα fusion oncoprotein. APL has the unique distinction of being the first and only malignancy in which high cure rates are achieved with targeted therapy, through the combination of two naturally 作者: 浪蕩子 時間: 2025-3-23 16:05 作者: 圓柱 時間: 2025-3-23 19:56 作者: 馬籠頭 時間: 2025-3-23 22:15
Shradhanjali Panda,Ananya Mitrant of all-. retinoic acid (ATRA) and arsenic trioxide (ATO). The identification of prognostic factors is a key process in clinical investigation, since their recognition allows the stratification of disease risks and promotes refined therapeutic adjustments. In fact, most treatments are now designed作者: Pepsin 時間: 2025-3-24 05:45
Spatial Linear Regression Models, of the molecular pathogenesis of APL has provided a mechanistic basis for the successful clinical use of . retinoic acid (ATRA) as well as arsenic trioxide (ATO) in targeting the PML/RARa fusion protein, which is pivotal in the pathogenesis of the disease. Although the advent of molecularly targete作者: mechanism 時間: 2025-3-24 08:37 作者: hypertension 時間: 2025-3-24 13:30
Causation, Laws and Regularitiessted the potent activity of all-. retinoic acid (ATRA) in APL, leading to differentiation of the malignant cells and complete remission. In the 1990s, arsenic trioxide (ATO) was also shown to lead to differentiation of the promyelocytes. Thus, the current treatment for newly diagnosed standard-risk 作者: 使迷惑 時間: 2025-3-24 16:04
https://doi.org/10.1007/978-3-031-59135-8omyelocytic leukemia (PML) and the retinoic acid receptor alpha (RARA) gene. The fusion gene results in a chimeric PML-RARA oncoprotein which plays a causative role in APL pathogenesis [1]. The gene fusion is readily detectable at diagnosis with sensitive PCR techniques and is an extremely reliable 作者: osteopath 時間: 2025-3-24 19:44 作者: 會議 時間: 2025-3-25 00:33 作者: 檢查 時間: 2025-3-25 06:41
Causation, Laws and Regularitiesbility of disease-specific (targeted) treatments. Traditional cytotoxic chemotherapy is now combined with all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) to result in relapse rates lower than other subtypes of acute myeloid leukemia. APL, however, is unique among the subtyp作者: Neutral-Spine 時間: 2025-3-25 09:25
Foreign Language Teaching in China,nts, with very few relapses but higher early death and death in remission. ATRA-ATO combinations without CHT are at least as effective as classical regimens while being less myelosuppressive, thus constituting a very appealing approach to treat elderly patients.作者: Infect 時間: 2025-3-25 14:55 作者: 多嘴多舌 時間: 2025-3-25 18:56 作者: 支柱 時間: 2025-3-25 22:35 作者: reptile 時間: 2025-3-26 01:19 作者: Terminal 時間: 2025-3-26 06:50
https://doi.org/10.1007/978-3-319-64257-4APL Animal Models; APL coagulopathy; ATRA-ATO; MRD monitoring; autologous stem cell transplant; allogenei作者: 符合規(guī)定 時間: 2025-3-26 12:23
978-3-030-09713-4Springer International Publishing AG, part of Springer Nature 2018作者: 嚙齒動物 時間: 2025-3-26 14:21
Oussama Abla,Francesco Lo Coco,Miguel A. SanzFirst comprehensive text on acute promyelocytic leukemia in the last ten years.Summarizes historical, current, and future treatment strategies.Highlights the most recent therapeutic recommendations fo作者: 減弱不好 時間: 2025-3-26 20:52
http://image.papertrans.cn/a/image/144410.jpg作者: Concrete 時間: 2025-3-26 21:23
Foreign Language Teaching in China,nts, with very few relapses but higher early death and death in remission. ATRA-ATO combinations without CHT are at least as effective as classical regimens while being less myelosuppressive, thus constituting a very appealing approach to treat elderly patients.作者: Evolve 時間: 2025-3-27 03:19 作者: BRIDE 時間: 2025-3-27 06:57
APL Coagulopathy,gern und Aggressionen in positive Energien umwandeln? Wie k?nnen Sie zu einem vorurteilsfreien Arbeitsumfeld beitragen?..Wenn Sie die Empfehlungen der Autoren beherzigen, werden Sie als Führungskraft erfolgreicher sein und stressfreier mit Ihren Mitarbeitern zusammenarbeiten.978-3-8349-2991-4978-3-8349-6761-9作者: dearth 時間: 2025-3-27 12:17
First-Line Therapy: ATRA-ATO/Reduced Chemotherapy Approach,tig in wachsende M?rkte einzutreten. Vor allem in dem st?ndig wachsenden neuen Europa wird ein enormes Wachstumspotenzial gesehen. Die sich dadurch er?ffnenden Chancen sind mit gro?en Herausforderungen an das Person- management in allen Unternehmen verbunden. Internationale Personaleins?tze untersch作者: Conspiracy 時間: 2025-3-27 14:36 作者: 粗魯性質(zhì) 時間: 2025-3-27 17:50 作者: frivolous 時間: 2025-3-27 22:54 作者: Comedienne 時間: 2025-3-28 02:28
L variants that may represent therapeutic challenges..Written by top experts in the field, .Acute Promyelocytic Leukemia: A Clinical Guide .is a valuable resource for clinicians and researchers who treat and investigate this disease in children and adults...978-3-030-09713-4978-3-319-64257-4作者: STAT 時間: 2025-3-28 09:16 作者: Prostatism 時間: 2025-3-28 11:59 作者: 不溶解 時間: 2025-3-28 16:59
APL in Developing Countries: A Chemotherapy-Based Approach,978-3-322-85961-7作者: CANON 時間: 2025-3-28 19:59
Rik van der Linden,Maartje Schermerd PML likely explain its clinical superiority. Mutations that are associated with therapy resistance do not only occur on RA or arsenic binding sites, but also on the arsenic binding site of PML. Such direct involvement of PML and NBs in APL cure raises hopes for their harnessing in other leukemias 作者: BORE 時間: 2025-3-29 00:00 作者: 補助 時間: 2025-3-29 04:49 作者: 迫擊炮 時間: 2025-3-29 10:37 作者: RALES 時間: 2025-3-29 13:41
Spatial Linear Regression Models, treatment regimens also the pyrimidine analog cytarabine. In order to achieve the highest rates of cure, these chemotherapy agents are used in combination with ATRA ± ATO in high-risk APL. This chapter will focus on the role of first-line chemotherapy agents in combination with ATRA for APL. While 作者: INCH 時間: 2025-3-29 16:20 作者: 容易懂得 時間: 2025-3-29 20:42
https://doi.org/10.1007/978-3-031-59135-8with readministration of ATRA and chemotherapy as salvage therapy, generally containing high-dose cytarabine and an anthracycline, followed by further post-remission chemotherapy and/or HSCT. ATO-based regimens are presently regarded as the first option for treatment of relapsed APL. The selection o作者: enormous 時間: 2025-3-29 23:55
Can We Make the Projects Easier? (Part 1)d to local resources, which requires a thorough analysis of efficacy, toxicity, infrastructure, and costs by a panel of local and international experts. With this aim in mind, the International Consortium on Acute Promyelocytic Leukemia (IC-APL) was founded in 2004 as an initiative supported by the 作者: 有說服力 時間: 2025-3-30 05:40
A Quest for Projects with Scarce Resourcestives, either alone or in combination. There is limited data on the kinetics of leukemia clearance and normal hematopoietic recovery after the administration of single agent ATO for the treatment of APL, but preliminary data suggests that it is likely to be different from conventional therapy. There作者: 消瘦 時間: 2025-3-30 08:16 作者: 暫時中止 時間: 2025-3-30 15:04
Inferences from Statistics to Causationrobably benefit from prolonged application of ATO. Even after frontline therapy with ATO, salvage therapy with ATO may still be effective. This chapter gives an overview on the currently available treatment options for relapsed APL, as well as on prognostic factors, which may influence the relapse management in the individual patient.作者: opalescence 時間: 2025-3-30 18:29
Causation, Laws and Regularitiesat diagnosis has been utilized to distinguish two risk groups (standard and high risk) on recent pediatric clinical trials to allow risk-adapted therapy. Current research efforts focus on the incorporation of ATO into treatment regimens and further defining risk factors for early death and relapse.作者: urethritis 時間: 2025-3-30 21:31 作者: crockery 時間: 2025-3-31 00:50 作者: FOLLY 時間: 2025-3-31 05:16
https://doi.org/10.1007/978-3-031-59135-8causative role in APL pathogenesis [1]. The gene fusion is readily detectable at diagnosis with sensitive PCR techniques and is an extremely reliable target to monitor the residual disease at the molecular level. We will discuss the evolution and importance of minimal residual disease (MRD) monitoring in APL.作者: 啜泣 時間: 2025-3-31 09:18 作者: –LOUS 時間: 2025-3-31 16:18
Mary Jean Walker,Wendy A. Rogersderived compounds, all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). The efficacy of these two agents against the disease and their synergistic and curative potential was predicted by transgenic murine models, which were equally instrumental in unlocking the molecular pathogenesis of APL.作者: Crumple 時間: 2025-3-31 18:53 作者: 褻瀆 時間: 2025-4-1 01:34 作者: ESPY 時間: 2025-4-1 04:45
Causation, Laws and Regularitiesecommended in addition to combination ATRA and ATO. A once highly fatal disease has now become the most highly curable subtype of acute myeloid leukemia, in most cases without the need for chemotherapy.
